Press Release:

CYTOCHROMA TO PRESENT AT BIOCENTURY’S 2009 FUTURE LEADERS IN THE BIOTECH INDUSTRY CONFERENCE

Markham, Ontario, Canada —March 26, 2009 — Cytochroma Inc. today announced that Charles W. Bishop, PhD, President and CEO, will be presenting a corporate overview at BioCentury’s 16th Annual Future Leaders in the Biotech Industry Conference.  The presentation will take place at 3:30 PM EDT on Thursday, April 2, 2009 at the Millennium Broadway Hotel & Conference Center in New York City.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD.  Cytochroma has three product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency.  In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.

For information contact:

Investors:
Gordon Ngan
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333
gngan@cytochroma.com

Media:
Robert Stanislaro
FD
Tel: +1 (212) 850-5657
robert.stanislaro@fd.com

< go back >